Alpha Cognition Inc. Common Stock

What they do

Alpha Cognition launched ZUNVEYL on March 19, 2025, and targets the largest-volume nursing homes specializing in Alzheimer's disease with an account-based long-term care sales team. It positions ZUNVEYL with Medicare payors and builds partnerships with consultant pharmacists and long-term care pharmacies. Three pre-clinical programs remain: ZUNVEYL plus memantine for moderate-to-severe Alzheimer's, an ALPHA-1062 sublingual formulation for Alzheimer's and mTBI, and Progranulin programs for ALS and SMA.

Revenue drivers

• ZUNVEYL net product revenue — Sales of the FDA-approved oral tablet, priced at a WAC of $869.36 per month; Q4 2025 net product revenue was approximately $2.5 million and launch-to-date net product revenue through year-end 2025 was approximately $6.8 million.
• Licensing revenue — Total 2025 revenue of approximately $10.2 million included licensing revenue in addition to net product revenue; quarterly total revenue reached $6.1 million in the quarter ended 2026-06-30.
• Long-term care channel — Revenue is driven by bottles dispensed into nursing homes; Q4 2025 bottles dispensed were 4,941, up 62% quarter-over-quarter, with December the strongest month at 1,859 bottles and 1,986 homes reached in the quarter.

Recent performance

Full-year 2025 revenue was $10.2 million, with fourth-quarter 2025 ZUNVEYL net product revenue of approximately $2.5 million and launch-to-date net product revenue of approximately $6.8 million. Quarterly total revenue grew from $2.8 million in each of the September and December 2025 quarters to $3.5 million in the March 2026 quarter and $6.1 million in the June 2026 quarter. Net loss widened to $20.7 million in 2025 from $14.8 million in 2024, and operating cash flow was negative $20.4 million in 2025. At June 30, 2026, the company reported $41.4 million in cash and cash equivalents, total assets of $64.5 million, total liabilities of $11.6 million and shareholder equity of $53.0 million.

Strategy

Management's principal objective is commercial success for ZUNVEYL in the long-term care market, where it has built a dedicated salesforce and targets high-volume Alzheimer's nursing homes. The company executed a second national PBM agreement in the fourth quarter of 2025 and now has agreements with two of the four major PBMs relevant to long-term care. It plans to sharpen ZUNVEYL's positioning through studies including the ongoing BEACON real-world effectiveness study and planned CONVERGE and RESOLVE studies. Pre-clinical assets are to be pursued only when timing and cost permit, and in January 2025 the company reverted rights to ALPHA-1062 for mTBI and acute pancreatitis.

Risks

• Commercial adoption uncertainty — The 10-K states ZUNVEYL may fail to achieve the broad adoption by physicians, patients, payors and others needed for commercial success, and the market opportunity may be smaller than anticipated.
• Dependence on third-party manufacturers — The company relies on third-party suppliers for commercial supply of ZUNVEYL, and the 10-K flags supply chain risks relating to Taiwan, including foreign economic downturns and political instability.
• Need for additional capital — The 10-Q states management will need to raise additional capital for planned R&D, continued ZUNVEYL commercialization and operating costs, and that financing may not be available on acceptable terms or at all.
• History of losses and negative cash flow — Alpha Cognition reported net losses of $13.8 million in 2023, $14.8 million in 2024 and $20.7 million in 2025, with operating cash flow of negative $20.4 million in 2025 and an accumulated deficit of $112,374,533 at June 30, 2026.

Outlook

At the time of its March 2026 fiscal 2025 release, management said it entered 2026 well capitalized with $66 million in cash and cash equivalents at year-end 2025 and reaffirmed a target of operating profitability in 2027, provided the long-term care commercial plan executes and pipeline compounds are not advanced. The company expects payer pull-through to improve in 2026 and continues to expect two product approvals ex-US via its partner CMS in Asia. It plans to present new ZUNVEYL clinical data at AAGP and the NEI Spring Congress in the second quarter of 2026 and to initiate the CONVERGE and RESOLVE studies.